Evidence map›Paper›PMID 35069088›Full record

ArticleCurrent urology2021

Expression of proto-oncogene c-Myc in patients with urinary bladder transitional cell carcinoma.

Charalampos Fragkoulis, Georgios Ntoumas, Ioannis Glykas, Georgios Papadopoulos, Georgios Stathouros, Akrivi Kostopoulou, Theodosia Choreftaki, Konstantinos Ntoumas

Open access · diamondAbstract read
In one paragraph

Article in Current urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. JUNB and JUND in Urological Cancers: A Literature Review.Current issues in molecular biology · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Charalampos FragkoulisUrology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
Georgios NtoumasMedical School, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis GlykasUrology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
Georgios PapadopoulosUrology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
Georgios StathourosUrology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
Akrivi KostopoulouPathology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
Theodosia ChoreftakiPathology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
Konstantinos NtoumasUrology Department, General Hospital of Athens G.N.A. "G. Gennimatas", Athens, Greece.
General Hospital of Athens G. Genimatas · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundc-Myc is a proto-oncogene located on human chromosome 8. It encodes a transcriptional factor which regulates the expression of approximately 10% to 15% of human genes, playing a crucial role in cell growth, differentiation, cellular metabolism, apoptosis, and cell transformation. The aim of this study is to correlate the expression of c-Myc in patients suffering from urinary bladder transitional cell carcinoma with tumor grade, stage, and lymph node metastases. MATERIALS AND

methodsFormalin-fixed, paraffin-embedded tissue samples were obtained from 54 consecutive patients who underwent transurethral resection of bladder tumor or radical cystectomy (RC) as treatment for urinary bladder transitional cell carcinoma. Immunohistochemistry was performed using c-Myc monoclonal antibody and c-Myc expression was then analyzed for correlation with tumor stage, grade, and lymph node metastases.

resultsFrom a total of 54 patients, 42 (77.8%) had c-Myc positive staining and 12 (22.2%) were c-Myc negative. In the c-Myc positive group, 28 patients (66.7%) had low grade tumors and 33 (78.6%) presented with non-muscle-invasive disease (

conclusionsIn our study, c-Myc negative staining was associated with higher grade and higher stage disease. On the contrary, most c-Myc positive tumors were low grade and non-muscle-invasive disease. In patients who underwent RC, c-Myc negative staining was associated with lymph node metastases.

Indexed as

Bladder cancerc-Myc expressionc-Myc proto-oncogeneTransitional cell carcinomaUrothelial carcinoma

Identifiers

PMID35069088
PMCPMC8772624
OpenAlexW3210499234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.